Discover and read the best of Twitter Threads about #VTE
Most recents (14)
As someone just getting started in IC, this talk by @jaygirimd was inspiring. #VTE/#PERT is such an exciting space with rapid development & study 🙌🏽
(Also shoutout to my mentor @GoldbergJBCTMD who’s work is displayed in Dr Giri’s slides)
My takeaways, a🧵:
(1/6)
#Fellows2023
(Also shoutout to my mentor @GoldbergJBCTMD who’s work is displayed in Dr Giri’s slides)
My takeaways, a🧵:
(1/6)
#Fellows2023
🔹Risk stratification and patient selection is key.
🔸Risk scores may not accurately stratify younger patients
🔹Full risk assessment has to include with the bedside eval w/ imaging + lab markers as adjunctive data
🔸Be on the lookout for normotensive shock
#Fellows2023 (2/6)
🔸Risk scores may not accurately stratify younger patients
🔹Full risk assessment has to include with the bedside eval w/ imaging + lab markers as adjunctive data
🔸Be on the lookout for normotensive shock
#Fellows2023 (2/6)
🔹Patients can be sick - upfront MCS with ECMO may be the first treatment needed in tackling high risk PE
🔸Contralateral arterial access during thrombectomy in case urgent MCS is needed
🔹always start with a RHC to establish severity of disease
#Fellows2023 (3/6)
🔸Contralateral arterial access during thrombectomy in case urgent MCS is needed
🔹always start with a RHC to establish severity of disease
#Fellows2023 (3/6)
@redcell_doc Sickle cell DISEASE has a unique reason for thromboembolism -- PE predominance - in situ or embolism from legs? Unclear still. But we know #SCT patients have higher D-dimer levels so maybe there's a hint for more in trait patients. #ASH22 2/n
@redcell_doc so, why not look into this diverse and high powered cohort? Did you know 80% of 23andme people consent to research cohort (caveat 90% of this cohort is from the United States)! #ASH22 3/n
🚨🚨📢📢 1/ Beyond thrilled to have our article published in @JACCJournals: “Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials”
jacc.org/doi/10.1016/j.…
Key findings highlighted ⬇️
jacc.org/doi/10.1016/j.…
Key findings highlighted ⬇️
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial thelancet.com/journals/lance…
We found that the higher dose did not reduce the risk of recurrent #VTE during the entire study period (Pregnancy plus postpartum period), which was unexpected and perhaps due to an over-enthusiastic sample size calculation…
1) Welcome to a new #accredited #tweetorial about an important complication of #pulmonaryembolism (#PE): chronic thromboembolic pulmonary hypertension #CTEPH. Follow this thread to earn 0.75h CE/#CME #physicians #physicianassociates #NPs #nurses #pharmacists.
2) I am Jason Weatherald @AlbertaPHdoc of @UAlberta and you may recall my previous tweetorial in this feed. It's still available for credit at cardiometabolic-ce.com/pah2/. @cardiomet_CE is your ONLY home for earning CE/#CME entirely on Twitter! Howdy to @vic_tapson @lauralynndonah1
3) This program is intended for #healthcare providers and is supported by educational grants from Actelion, Bayer, Chiesi, & AstraZeneca. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/. Prior programs, still available for credit, are at cardiometabolic-ce.com
1) Welcome to a new #accredited #tweetorial on managing #VTE at the extremes of weight & renal function. Free CE/#CME credit for following along with expert author @AryaRoopen from King’s Thrombosis Centre at King's College Hospital in London! Only the best for our learners!
2) When we think about "special populations" in #VTE, we think weight, age, and #cancer status. @aakonc already addressed the last of those (earn credit still at cardiometabolic-ce.com/antithrombotic…). Learn the rest here! Hello to @ProfMakris @bhwords @MiddeldorpS @fniainle @AliTaherMD
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures at cardiometabolic-ce.com/disclosures/. Credit for #physicians #physicianassociates #nurses #NPs #pharmacists
1) Welcome to a new #accredited #tweetorial on a🗝️ topic in #cancer care & #vascular medicine: #VTE (#DVT and #PE). Cancer patients are at⬆️risk from their disease, their comorbidities, & often from their treatment. It's a sticky wicket & @cardiomet_CE is proud to welcome ...
2) ... one of the world's leading authorities on cancer-associated VTE as new faculty both here and on @onc_ce: Dr. Alok Khorana @aakonc of @ClevelandClinic, to talk about advances and best treatment in this space!
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/. Earn CE/#CME credit from prior programs at cardiometabolic-ce.com.
Don’t miss a new accredited #tweetorial launching TOMORROW here on @cardiomet_CE. #Emergencymedicine #thrombosis researcher @md_pollack will be discussing safe, effective management of selected patients with venous thromboembolism (#VTE) from the #emergencydepartment.
It used to be SOOO much more complicated, but since we entered the era of the #DOACs, #lifeisgood! #Physicians #nurses #pharamcists all work together to make it happen, and all can earn CE/#CME here! @AlexSpyropoul @ScottKaatz @RenatoDLopes1 @GenoMerli @aakonc @vic_tapson
1) Welcome to a #tweetorial on the safe and effective management of acute venous #thromboembolism (#VTE) directly from the #emergencydepartment. This program is accredited for 0.50 credits for #physicians #nurses #pharmacists by @academiccme! I am @md_pollack.
1/ #Tweetorial Part 2- Now its time to talk about….
CHRONIC
C-L-O-T
#VTE #DVT #Thrombectomy #Lytics #Cardiotwitter #IRAD #Medthread #Clot @CardioBot @RadialFirstBot @BotPci @EPeeps_Bot @TAVRBot @MedTweetorials @UjjwalRastogiMD @Umair2017 @Umair2017 @VenuVadlamudiMD
CHRONIC
C-L-O-T
#VTE #DVT #Thrombectomy #Lytics #Cardiotwitter #IRAD #Medthread #Clot @CardioBot @RadialFirstBot @BotPci @EPeeps_Bot @TAVRBot @MedTweetorials @UjjwalRastogiMD @Umair2017 @Umair2017 @VenuVadlamudiMD
2/ How much time does it take for #ChronicClot to START to form?
#Fellowstwitter #fellows #fellowtwitter #medtwitter #Clottwitter #VTE @MedTweetorials @CardioBot #Tweetorial #Meded @GAEscobarMD @ekgpdx @HeartOTXHeartMD @EM_RESUS @Pooh_Velagapudi @Vascupedia_com @Dr_Bowser
#Fellowstwitter #fellows #fellowtwitter #medtwitter #Clottwitter #VTE @MedTweetorials @CardioBot #Tweetorial #Meded @GAEscobarMD @ekgpdx @HeartOTXHeartMD @EM_RESUS @Pooh_Velagapudi @Vascupedia_com @Dr_Bowser
Pulmonary #embolism (lung blood clot) was >10 times more common after #SARSCoV2 infection (COVID19; ~15x over background rate), vs after getting #Pfizer's or #AstraZeneca's vaccine (~1.2x> background)
Similar greater risks with COVID-19 for #DVT & #VTE
🧵
medrxiv.org/content/10.110…
Similar greater risks with COVID-19 for #DVT & #VTE
🧵
medrxiv.org/content/10.110…
2) First of all – as the authors note – in those #vaccinated against COVID-19, "thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia were very rare events."
3) Data from 1.9 Million (M) recipients of AstraZeneca, ~1.7 M of Pfizer, and ~300k COVID-19 cases (few old) – compared with ~2.3 M in the general population.
These cohorts were used to calculate the observed incidence vs. background (SIR) or observed vs. expected # of cases.
These cohorts were used to calculate the observed incidence vs. background (SIR) or observed vs. expected # of cases.
1/ Welcome to the first part of a #Tweetorial series on #VenousDisease.
🩸To begin how about we talk about the main player in the game- C.L.O.T. (and why you should care about it)
#Cardiotwitter #Irad #fellows #fellowtwitter #medthread #clot #medtwitter #clottwitter
🩸To begin how about we talk about the main player in the game- C.L.O.T. (and why you should care about it)
#Cardiotwitter #Irad #fellows #fellowtwitter #medthread #clot #medtwitter #clottwitter
2/ But first a question- Is there a difference between arterial and venous clot??
#Clot #cardiology #DVT #irad #VenousDisease #medthread #tweetorial #fellows @HadyLichaaMD @VladLakhter @agtruesdell @AntoniousAttall @TheNarulaSeries @t_intheleadcoat @ShariqShamimMD
#Clot #cardiology #DVT #irad #VenousDisease #medthread #tweetorial #fellows @HadyLichaaMD @VladLakhter @agtruesdell @AntoniousAttall @TheNarulaSeries @t_intheleadcoat @ShariqShamimMD
3/ All clots ARE NOT born equally! There is a difference!
Vaccine associated thrombocytopenic thrombosis from the eyes of general practice - a thread 🧵
#CovidVaccine #AZ
1/16
#CovidVaccine #AZ
1/16
2/16
The JCVI announcement today recommends to offer alternative #CovidVaccine to AZ in healthy adults < 30 years old (i.e. no underlying health conditions): gov.uk/government/pub…
The JCVI announcement today recommends to offer alternative #CovidVaccine to AZ in healthy adults < 30 years old (i.e. no underlying health conditions): gov.uk/government/pub…
3/16
This is following investigation into a blood clotting phenomenon DISTINCT from typical #VTE but clinically similar to heparin-induced thrombocytopenia (HIT) associated with thrombocytopenia and unusual site thrombosis (with a preponderance for CVST) post-AZ vaccination
This is following investigation into a blood clotting phenomenon DISTINCT from typical #VTE but clinically similar to heparin-induced thrombocytopenia (HIT) associated with thrombocytopenia and unusual site thrombosis (with a preponderance for CVST) post-AZ vaccination
Kicking off multidisciplinary Research Consensus Panel (RCP) to finally investigate the ❓: what is the optimal medical therapy (OMT) following venous recan? Follow #VenousRCP throughout the day to learn more and contribute! #SIRFoundation @SIRRFS @SIR_ECS @JVIRmedia
🔴 Pathophysiology of venous thromboembolism #VTE
🟠Venous recanalization & stenting
🟡The mystery of medical therapy following recanalization
🟢Patency & outcome measures
🔵Economics & cost-effectiveness of treatment
🟣Future directions
#VenousRCP
🟠Venous recanalization & stenting
🟡The mystery of medical therapy following recanalization
🟢Patency & outcome measures
🔵Economics & cost-effectiveness of treatment
🟣Future directions
#VenousRCP
🔴 ✅#VTE affects ~100 of every 100,000 people yearly in the US
✅Incidence of VTE ⬆️⬆️ exponentially with age, especially after 40
✅#Endovascular recan is a common tx; post-tx algorithms vary widely
✅More #epidemiology info @CircAHA bit.ly/37IptZh
@Pertconsortium
✅Incidence of VTE ⬆️⬆️ exponentially with age, especially after 40
✅#Endovascular recan is a common tx; post-tx algorithms vary widely
✅More #epidemiology info @CircAHA bit.ly/37IptZh
@Pertconsortium
(1/22) Acute PE treatment. An ever evolving landscape.
How about a #tweetorial on acute pulmonary embolism (#PE) and how to use mechanical #thombectomy with @InariMedical #FlowTriever?? Lets goooooo!
#InariFellowsEdition #IRad #IC #cardiotwitter
Pic credit @Jonathan_PaulMD
How about a #tweetorial on acute pulmonary embolism (#PE) and how to use mechanical #thombectomy with @InariMedical #FlowTriever?? Lets goooooo!
#InariFellowsEdition #IRad #IC #cardiotwitter
Pic credit @Jonathan_PaulMD
2/ From @CDCgov data one American dies of a blood clot every....? #VTE #PE @PERTConsortium #InariFellowsForum
3/ Acute #PE stats
📊100,000–180,000 PE-related deaths annually in US
📊PE is the most preventable cause of death among hospitalized patients
📊3rd leading cardiovascular cause of death after coronary disease and stroke
⏱ 1 American dies of a blood clot every 6 seconds
📊100,000–180,000 PE-related deaths annually in US
📊PE is the most preventable cause of death among hospitalized patients
📊3rd leading cardiovascular cause of death after coronary disease and stroke
⏱ 1 American dies of a blood clot every 6 seconds
